From the Department of Neurology (I.A.L., S.F.Z., M.B.W., R.L.S., T.L.-M., W.T.K., E.S.R.), Massachusetts General Hospital, Boston.
Department of Neurology, Yale School of Medicine, New Haven, CT (J.A.K).
Stroke. 2020 Apr;51(4):1128-1134. doi: 10.1161/STROKEAHA.119.028515. Epub 2020 Mar 11.
Background and Purpose- We evaluated the association between 2 types of predictors of delayed cerebral ischemia after nontraumatic subarachnoid hemorrhage, including biomarkers of the innate immune response and neurophysiologic changes on continuous electroencephalography. Methods- We studied subarachnoid hemorrhage patients that had at least 72 hours of continuous electroencephalography and blood samples collected within the first 5 days of symptom onset. We measured inflammatory biomarkers previously associated with delayed cerebral ischemia and functional outcome, including soluble ST2 (sST2), IL-6 (interleukin-6), and CRP (C-reactive protein). Serial plasma samples and cerebrospinal fluid sST2 levels were available in a subgroup of patients. Neurophysiologic changes were categorized into new or worsening epileptiform abnormalities (EAs) or new background deterioration. The association of biomarkers with neurophysiologic changes were evaluated using the Wilcoxon rank-sum test. Plasma and cerebrospinal fluid sST2 were further examined longitudinally using repeated measures mixed-effects models. Results- Forty-six patients met inclusion criteria. Seventeen (37%) patients developed new or worsening EAs, 21 (46%) developed new background deterioration, and 8 (17%) developed neither. Early (day, 0-5) plasma sST2 levels were higher among patients with new or worsening EAs (median 115 ng/mL [interquartile range, 73.8-197]) versus those without (74.7 ng/mL [interquartile range, 44.8-102]; =0.024). Plasma sST2 levels were similar between patients with or without new background deterioration. Repeated measures mixed-effects modeling that adjusted for admission risk factors showed that the association with new or worsening EAs remained independent for both plasma sST2 (β=0.41 [95% CI, 0.09-0.73]; =0.01) and cerebrospinal fluid sST2 (β=0.97 [95% CI, 0.14-1.8]; =0.021). IL-6 and CRP were not associated with new background deterioration or with new or worsening EAs. Conclusions- In patients admitted with subarachnoid hemorrhage, sST2 level was associated with new or worsening EAs but not new background deterioration. This association may identify a link between a specific innate immune response pathway and continuous electroencephalography abnormalities in the pathogenesis of secondary brain injury after subarachnoid hemorrhage.
背景与目的-我们评估了 2 种非创伤性蛛网膜下腔出血后迟发性脑缺血的预测因子之间的关联,包括固有免疫反应的生物标志物和连续脑电图上的神经生理变化。方法-我们研究了至少有 72 小时连续脑电图和在症状发作的前 5 天内采集的血液样本的蛛网膜下腔出血患者。我们测量了先前与迟发性脑缺血和功能结局相关的炎症生物标志物,包括可溶性 ST2(sST2)、白细胞介素-6(IL-6)和 C 反应蛋白(CRP)。在亚组患者中可获得连续的血浆样本和脑脊液 sST2 水平。神经生理变化分为新出现或恶化的癫痫样异常(EAs)或新出现的背景恶化。使用 Wilcoxon 秩和检验评估生物标志物与神经生理变化之间的关联。使用重复测量混合效应模型进一步纵向检查血浆和脑脊液 sST2。结果-46 名患者符合纳入标准。17 名(37%)患者出现新出现或恶化的 EAs,21 名(46%)患者出现新出现的背景恶化,8 名(17%)患者未出现。新出现或恶化的 EAs 患者的早期(第 0-5 天)血浆 sST2 水平较高(中位数 115ng/mL[四分位距,73.8-197]),而无 EAs 患者的血浆 sST2 水平较低(74.7ng/mL[四分位距,44.8-102];=0.024)。新出现背景恶化患者的血浆 sST2 水平与无新出现背景恶化患者的血浆 sST2 水平相似。在调整入院危险因素后,重复测量混合效应模型显示,新出现或恶化的 EAs 与血浆 sST2(β=0.41[95%CI,0.09-0.73];=0.01)和脑脊液 sST2(β=0.97[95%CI,0.14-1.8];=0.021)均存在独立关联。IL-6 和 CRP 与新出现的背景恶化或新出现或恶化的 EAs 均无关联。结论-在因蛛网膜下腔出血而入院的患者中,sST2 水平与新出现或恶化的 EAs 相关,但与新出现的背景恶化无关。这种关联可能表明特定的固有免疫反应途径与蛛网膜下腔出血后继发性脑损伤的连续脑电图异常之间存在联系。